HER2 therapy: Molecular mechanisms of trastuzumab resistance

trastuzumab Trastuzumab exposure for a relatively short period does not seem to substantially affect the pregnancy outcome In contrast, a more prolonged

Trastuzumab is a biologic antineoplastic agent that, at the time of its FDA approval in 1998, was among the first available targeted chemotherapies  trastuzumab For treating certain types of breast, stomach or esophagus cancers, and othersTrastuzumab is available as a biosimilar medication See our biosimilar pamphlet